Aortic coarctation is a congenital heart defect characterized by a narrowing of the aorta, which can lead to increased blood pressure and other cardiovascular complications. While specific companies may not be exclusively dedicated to aortic coarctation, various medical device and healthcare companies provide products and technologies used in the treatment and management of congenital heart defects.
Latest Aortic Coarctation Companies Updates:
Artivion, a leading cardiac and vascular surgery company, announced positive real-world data from its On-X Aortic Heart Valve Low INR post-market study. The data showed that the On-X valve remains safe and effective with low-dose warfarin, potentially improving patient outcomes and reducing bleeding risks.
Edwards Lifesciences, a major player in heart valve technology, received FDA approval for its Sapien 3 Ultra Transcatheter Aortic Valve System for the treatment of severe aortic stenosis in patients with bicuspid aortic valves. This approval expands treatment options for a challenging patient population.
Medtronic, another industry leader, showcased its Hugo™ Robotic-Assisted Surgery System at the recent Transcatheter Cardiovascular Therapeutics (TCT) meeting. The Hugo system has the potential to revolutionize minimally invasive aortic coarctation repair by enhancing precision and reducing complications.
List of Aortic Coarctation Key companies in the market:
Aortic Coarctation Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)